Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats

Neuroscience. 2009 Jan 23;158(2):558-69. doi: 10.1016/j.neuroscience.2008.10.023. Epub 2008 Nov 1.

Abstract

The neurotoxin 6-hydroxydopamine has been widely used to model aspects of Parkinson's disease in rodents, but the mechanisms underlying toxin-induced dopaminergic degeneration and functional impairment have not been fully elucidated. The main aim of the present study was to assess a possible role for calpains in neurochemical and behavioral deficits following unilateral infusion of intrastriatal 6-hydroxydopamine in adult rats. Toxin administration produced a profound dopaminergic denervation, as indicated by a 90-95% reduction in dopamine transporter radiolabeling measured in the caudate-putamen at 2 weeks post-lesion. Treatment with 6-hydroxydopamine also resulted in calpain activation in both caudate-putamen and substantia nigra, as measured by the appearance of calpain-specific spectrin breakdown products. Calpain activation peaked at 24 h after 6-hydroxydopamine infusion and remained elevated at later time points. In contrast, caspase-3-mediated spectrin cleavage subsided within 48 h in both brain areas. In a subsequent experiment, calpain inhibition was achieved by intrastriatal infusion of an adenovirus expressing the endogenous calpain inhibitor, calpastatin. Calpastatin delivery abolished the lesion-induced calpain-mediated spectrin cleavage and alleviated forelimb asymmetries resulting from unilateral intrastriatal 6-hydroxydopamine. Unexpectedly, dopamine transporter and tyrosine hydroxylase labeling revealed significant neuroprotection, not in the nigrostriatal pathway but rather in the ventral tegmental area. These findings support a role for calpain activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. However, after near-total dopaminergic depletion, the primary benefit of calpain inhibition may not occur within the nigrostriatal dopaminergic pathway itself.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Agents / administration & dosage*
  • Animals
  • Autoradiography
  • Calcium-Binding Proteins / pharmacology
  • Calpain / antagonists & inhibitors
  • Calpain / metabolism*
  • Caspase 3 / metabolism
  • Cocaine / analogs & derivatives
  • Cocaine / metabolism
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism
  • Dopamine / metabolism*
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Functional Laterality / drug effects
  • Green Fluorescent Proteins / genetics
  • Male
  • Motor Activity / drug effects*
  • Oxidopamine / administration & dosage*
  • Psychomotor Performance / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Spectrin / metabolism
  • Time Factors
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Adrenergic Agents
  • Calcium-Binding Proteins
  • Dopamine Plasma Membrane Transport Proteins
  • Spectrin
  • Green Fluorescent Proteins
  • 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane
  • calpastatin
  • Oxidopamine
  • Tyrosine 3-Monooxygenase
  • Calpain
  • Caspase 3
  • Cocaine
  • Dopamine